Cellectar Biosciences Reports Case Study of Long-Lasting Response
The case study highlights a complete response lasting more than eight years in a heavily pretreated patient with DLBCL treated with iopofosine I 131.
Related stories
Shira Real Estate Development and Investments Reports Q3 Loss of 112,814 Dinars
M impact | EQUITY | Oct 29, 2026, 12:18 PM UTC
Arab Aluminium Industry Reports Q3 Profit of 6,093 Dinars
M impact | EQUITY | Oct 29, 2026, 12:18 PM UTC
Quanome Technologies Enters Second GPU Server Purchase Agreement
Quanome Technologies entered a second purchase agreement for 32 GPU server units at $18.80 million.
L impact | EQUITY | Oct 29, 2026, 12:18 PM UTC
Silicom Reports Q3 Revenue of $26.7M, Adjusted EPS of $0.04
M impact | EQUITY | Oct 29, 2026, 12:18 PM UTC
Shengyi Electronics Says Q3 Revenue Rose 23% Year Over Year
M impact | EQUITY | Oct 29, 2026, 12:18 PM UTC
Boliden's Adjusted Operating Profit Jumps 77% in Third Quarter
Boliden said stronger metal prices and performance across its mines and smelters aided the increase.
M impact | EQUITY | Oct 29, 2026, 12:18 PM UTC